1. Specifications table {#s0005}
=======================

Subject areaBiologyMore specific subject areaEnzyme kinetics, high-throughput drug screenType of dataTableHow data was acquiredLiterature searchData formatRaw text filesExperimental factorsNot applicableExperimental featuresIdentities of aminoacyl-tRNA synthetases containing cis editing domains, proteins capable of trans-editing of misacylated tRNAs, cyclodipeptide synthases, and variants of these proteins that have extended substrate specificitiesData source locationShreveport, LA, USAData accessibilityData are available here with this article

1.1. Value of the data {#s0010}
----------------------

•Provides a blueprint for designing high-throughput assays for aminoacyl-tRNA synthetases•Identifies editing domains and other proteins that can be used to regenerate free tRNA from the aminoacyl-tRNA product, decreasing the cost and increasing the sensitivity of aminoacyl-tRNA synthetase assays•Facilitates the development of high throughput screens for inhibitors of at least 16 of the 20 naturally occurring aminoacyl-tRNA synthetases

2. Data, experimental design, materials and methods {#s0015}
===================================================

Aminoacyl-tRNA synthetases (aaRSes) are essential enzymes that catalyze the attachment of amino acids to their cognate tRNAs using a two-step mechanism ([Fig. 1](#f0005){ref-type="fig"}). In the first step, the amino acid is activated by ATP, forming an enzyme-bound aminoacyl-adenylate intermediate (aaRS•AA-AMP). In the second step of the reaction, the activated aminoacyl-moiety is transferred to the 3׳ end of the cognate tRNA, resulting in the release of the aminoacyl-tRNA and AMP products.

We have developed a continuous spectrophotometric assay for one of the aminoacyl-tRNA synthetases, tyrosyl-tRNA synthetase, in which the release of AMP is coupled to the production of NADH via AMP deaminase (which converts AMP to IMP) and IMP dehydrogenase (which couples the reduction of NAD^+^ to the conversion of IMP to XMP). As the production of NADH is associated with an increase in absorbance at 340 nm, the aminoacylation of tRNA^Tyr^ by tyrosine can be monitored spectrophotometrically. In contrast to other aminoacyl-tRNA synthetase assays, where tRNA is the limiting substrate, in the tyrosyl-tRNA synthetase assay, the Tyr-tRNA^Tyr^ product is cleaved, regenerating the tRNA^Tyr^ substrate. This results in a substantial increase in the sensitivity of the assay, while significantly decreasing its cost. We have demonstrated that the tyrosyl-tRNA synthetase assay can be used to monitor the aminoacylation of tRNA by either [l]{.smallcaps}- or [d]{.smallcaps}-tyrosine, with cyclodityrosine synthase and [d]{.smallcaps}-tyrosyl-tRNA deacylase being used to cleave the [l]{.smallcaps}-Tyr-tRNA and [d]{.smallcaps}-Tyr-tRNA products, respectively. A detailed description of this assay can be found in [@bib1].

In order to extend the tyrosyl-tRNA synthetase assay to other aminoacyl-tRNA synthetases, we have identified aminoacyl-tRNA synthetase editing domains, trans-editing proteins, and cyclodipeptide synthases that can be used to cleave specific aminoacyl-tRNA products. In addition, based on published literature, we have identified variants of editing domains and proteins that increase the number of different aminoacyl-tRNAs that the editing domains and proteins can cleave. This allows them to regenerate the tRNA substrate for several different aminoacyl-tRNA synthetases.

The basic aminoacyl-tRNA synthetase assay is shown in [Fig. 2](#f0010){ref-type="fig"}. Aminoacylation of tRNA results in the release of the aminoacyl-tRNA product, AMP, and inorganic pyrophosphate (PP~i~). We have coupled the production of AMP to the reduction of NAD^+^, allowing the assay to be followed by monitoring changes in absorbance at 340 nm (ε~340~^NADH^=6220 M^−1^ cm^−1^). Alternatively, the reaction can be followed by using inorganic pyrophosphatase to cleave the inorganic pyrophosphate product and monitoring the resulting production of phosphate (e.g. via reaction with malachite green and ammonium molybdate [@bib2; @bib3]). Cleavage of the aminoacyl-tRNA product is achieved by using an editing domain, trans-editing protein, or cyclodipeptide synthase that is specific for each particular aminoacyl-tRNA, or by using the M129K variant of [d]{.smallcaps}-tyrosyl-tRNA deacylase, which is proposed to catalyze the hydrolysis of both [l]{.smallcaps}- and [d]{.smallcaps}-aminoacyl-tRNAs and has a broad specificity with respect to the aminoacyl moiety ([Table 1](#t0005){ref-type="table"}). In the event that a particular editing domain cannot be isolated in its active form, a variant of the full length aminoacyl-tRNA synthetase in which the synthetic site has been inactivated can be used to hydrolyze the aminoacyl-tRNA product.
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![Two step reaction mechanism for the aminoacylation of tRNA. The amino acid activation and subsequent transfer of the activated aminoacyl moiety to tRNA is shown. 'aaRS', AA, and PP~i~ represent aminoacyl-tRNA synthetase, amino acid, and inorganic pyrophosphate, respectively. Noncovalent interactions are indicated by '•' and covalent bonds are indicated by '-'.](gr1){#f0005}

![Reaction scheme for the aminoacyl-tRNA synthetase assay. The aminoacylation of tRNA is monitored by coupling the release of AMP to the production of NADH via the actions of AMP deaminase and IMP dehydrogenase. Under conditions where tRNA aminoacylation is the rate-limiting step (i.e., at sufficiently low concentrations of the aminoacyl-tRNA synthetase), the rate of the reaction will correspond to the increase in absorbance at 340 nm with respect to time. Cleavage of the aminoacyl-tRNA (AA-tRNA) product by an aminoacyl-tRNA editing protein or cyclodipeptide synthase, regenerates the unliganded tRNA, preventing it from being the limiting substrate in the reaction. AMP, IMP, XMP, PP~i~, and AA represent adenosine 5′-monophosphate, inosine 5′-monophosphate, xanthine 5′-monophosphate, inorganic pyrophosphate, and amino acid, respectively.](gr2){#f0010}

###### 

Proteins that regenerate free tRNA.

  **Protein**[a](#tbl1fna){ref-type="table-fn"}                                          **Substrate specificity**[b](#tbl1fnb){ref-type="table-fn"}                     **Literature references**
  -------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ---------------------------
  IleRS editing domain[c](#tbl1fnc){ref-type="table-fn"}                                 [l]{.smallcaps}-Val-tRNA                                                        [@bib4; @bib5]
  ValRS editing domain[c](#tbl1fnc){ref-type="table-fn"}                                 [l]{.smallcaps}-Thr-tRNA                                                        [@bib4]
  LeuRS editing domain[c](#tbl1fnc){ref-type="table-fn"}                                 [l]{.smallcaps}-Ile-tRNA, [l]{.smallcaps}-Met-tRNA, [l]{.smallcaps}-Nva-tRNA    [@bib6; @bib7]
  LeuRS-T252A editing domain[c](#tbl1fnc){ref-type="table-fn"}                           [l]{.smallcaps}-Ile-tRNA, [l]{.smallcaps}-Met-tRNA, [l]{.smallcaps}-Nva-tRNA,   [@bib8; @bib9]
  [l]{.smallcaps}-Leu-tRNA                                                                                                                                               
  ThrRS editing domain[c](#tbl1fnc){ref-type="table-fn"}                                 [l]{.smallcaps}-Ser-tRNA                                                        [@bib10]
  ProRS editing domain[c](#tbl1fnc){ref-type="table-fn"}                                 [l]{.smallcaps}-Ala-tRNA                                                        [@bib11]
  PheRS editing domain[c](#tbl1fnc){ref-type="table-fn"}                                 [l]{.smallcaps}-Tyr-tRNA                                                        [@bib12]
  Ybak protein[d](#tbl1fnd){ref-type="table-fn"}                                         [l]{.smallcaps}-Cys-tRNA                                                        [@bib13]
  ProXP-Ala protein[d](#tbl1fnd){ref-type="table-fn"}                                    [l]{.smallcaps}-Ala-tRNA                                                        [@bib14]
  AlaX protein[d](#tbl1fnd){ref-type="table-fn"}                                         [l]{.smallcaps}-Ser-tRNA, Gly-tRNA                                              [@bib15]
  PrdX protein[d](#tbl1fnd){ref-type="table-fn"}                                         [l]{.smallcaps}-Ala-tRNA                                                        [@bib15]
  ThrRS-ed protein[d](#tbl1fnd){ref-type="table-fn"}                                     [l]{.smallcaps}-Ser-tRNA                                                        [@bib16]
  D-tyrosyl-tRNA deacylase (DTD)[d](#tbl1fnd){ref-type="table-fn"}                       [d]{.smallcaps}-aminoacyl-tRNA                                                  [@bib17; @bib18]
                                                                                                                                                                         
  D-tyrosyl-tRNA deacylase M129K variant (DTD-M129K)[e](#tbl1fne){ref-type="table-fn"}   [l]{.smallcaps}-Ala-tRNA, [l]{.smallcaps}-Asp-tRNA, [l]{.smallcaps}-Arg-tRNA,   [@bib19]
  [l]{.smallcaps}-Cys-tRNA, Gly-tRNA, [l]{.smallcaps}-Glu-tRNA, l-Leu-tRNA,                                                                                              
  [l]{.smallcaps}-Phe-tRNA, [l]{.smallcaps}-Pro-tRNA, [l]{.smallcaps}-Ser-tRNA,                                                                                          
  [l]{.smallcaps}-Thr-tRNA, [l]{.smallcaps}-Tyr-tRNA, l-Val-tRNA                                                                                                         
  AlbC[f](#tbl1fnf){ref-type="table-fn"}                                                 [l]{.smallcaps}-Phe-tRNA                                                        [@bib20]
  Cyclodityrosine synthase[f](#tbl1fnf){ref-type="table-fn"}                             [l]{.smallcaps}-Tyr-tRNA                                                        [@bib21]
  YvmC[f](#tbl1fnf){ref-type="table-fn"}                                                 [l]{.smallcaps}-Leu-tRNA                                                        [@bib22]

aminoacyl-tRNA synthetases are abbreviated using the 3-letter code for the amino acid, followed by 'RS'.

standard 3-letter codes are used for each aminoacyl-tRNA, Nva is the 3-letter code for norvaline.

indicates the activity of the editing domain in the protein.

indicates a naturally occurring trans-editing protein.

hydrolysis of [l]{.smallcaps}-aminoacyl-tRNAs is assumed based on the ability of the DTD-M129K variant to bind the free [l]{.smallcaps}-amino acids.

indicates a cyclodipeptide synthase, which releases the free tRNA along with a cyclic dipeptide.
